Patent 12071391 was granted and assigned to Atossa Therapeutics, Inc. on August, 2024 by the United States Patent and Trademark Office.
The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.